Biotech Profile
Hemispherian – First-in-Class TET2 Agonist Tackles Glioblastoma Through DNA Demethylation
Norwegian Biotech Secures FDA IND Clearance for Novel Mechanism in Brain Cancer Norwegian biotech Hemispherian brings a distinctive approach to glioblastoma treatment with GLIX1, a first-in-class small-molecule TET2 agonist that recently cleared an IND with the U.S. FDA. CEO Zeno
22 October 2025